Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised

Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests

More from Archive

More from Pink Sheet